Can I read Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution on EtoBox?

Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution by Toshihiko Masui; Kazuyuki Nagai; Takayuki Anazawa; Asahi Sato; Yuichiro Uchida; Kenzo Nakano; Akitada Yogo; Akihiro Kaneda; Naoto Nakamura; Michio Yoshimura; Takashi Mizowaki; Norimitsu Uza; Akihisa Fukuda; Shigemi Matsumoto; Masashi Kanai; Hiroyoshi Isoda; Masaki Mizumoto; Satoru Seo; Koichiro Hata; Kojiro Taura; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto; Etsuro Hatano is a Medicine article available to read on EtoBox.

What is Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution about?

## Abstract ## Background Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). ## Methods A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. ## Results Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good t

Who reads Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution?

Author

Toshihiko Masui; Kazuyuki Nagai; Takayuki Anazawa; Asahi Sato; Yuichiro Uchida; Kenzo Nakano; Akitada Yogo; Akihiro Kaneda; Naoto Nakamura; Michio Yoshimura; Takashi Mizowaki; Norimitsu Uza; Akihisa Fukuda; Shigemi Matsumoto; Masashi Kanai; Hiroyoshi Isoda; Masaki Mizumoto; Satoru Seo; Koichiro Hata; Kojiro Taura; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto; Etsuro Hatano

Publisher

Springer Science and Business Media LLC

Published

2022

Language

EN

Field

Medicine (Health Sciences)